

# HÃ©ctor Escobar-Morreale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5693298/publications.pdf>

Version: 2024-02-01

224  
papers

18,545  
citations

18465

62  
h-index

13365

130  
g-index

227  
all docs

227  
docs citations

227  
times ranked

11989  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining PCOS: A syndrome with an intrinsic heterogeneous nature. , 2022, , 3-13.		4
2	High serum copeptin may be a marker of an increased carotid intima-media thickness in asymptomatic patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108085.	1.2	0
3	Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours. Scientific Reports, 2022, 12, 2671.	1.6	10
4	Impact of excluding hyperglycemia from international diabetes federation metabolic syndrome diagnostic criteria on prevalence of the syndrome and its association with microvascular complications, in adult patients with type 1 diabetes. Endocrine, 2022, 76, 601-611.	1.1	2
5	Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis. Human Reproduction Update, 2022, 28, 501-517.	5.2	13
6	A Proposal for Nomenclature Revision of Nonfunctioning Adrenal Incidentalomas as Adrenal Lesions of Undetermined Secretion of Adrenal Steroids (ALUSAS). Endocrine Practice, 2022, 28, 918-920.	1.1	8
7	Effect of Iron Depletion by Bloodletting vs. Observation on Oxidative Stress Biomarkers of Women with Functional Hyperandrogenism Taking a Combined Oral Contraceptive: A Randomized Clinical Trial. Journal of Clinical Medicine, 2022, 11, 3864.	1.0	2
8	Multidisciplinary protocol of preoperative and surgical management of patients with pituitary tumors candidates to pituitary surgery. Annales D'Endocrinologie, 2021, 82, 20-29.	0.6	10
9	Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review. Endocrine, 2021, 72, 40-48.	1.1	20
10	Fasting serum copeptin and asymptomatic peripheral artery disease: No association in patients with type 1 diabetes mellitus. Diabetes and Metabolism, 2021, 47, 101207.	1.4	3
11	Acute-phase glycoprotein profile responses to different oral macronutrient challenges: Influence of sex, functional hyperandrogenism and obesity. Clinical Nutrition, 2021, 40, 1241-1246.	2.3	11
12	Iron Overload in Functional Hyperandrogenism: In a Randomized Trial, Bloodletting Does Not Improve Metabolic Outcomes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1559-e1573.	1.8	6
13	Postprandial responses of circulating energy homeostasis mediators to single macronutrient challenges: influence of obesity and sex hormones. Food and Function, 2021, 12, 1051-1062.	2.1	5
14	Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas. Hormones, 2021, 20, 735-744.	0.9	8
15	Remission of Diabetes Following Bariatric Surgery: Plasma Proteomic Profiles. Journal of Clinical Medicine, 2021, 10, 3879.	1.0	8
16	Type 1 diabetes mellitus and polycystic ovary syndrome. Nature Reviews Endocrinology, 2021, 17, 701-702.	4.3	5
17	Diagnostic Challenges in Nonclassical Congenital Adrenal Hyperplasia. , 2021, , 53-61.		0
18	Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion. Scientific Reports, 2021, 11, 20539.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Bloodletting has no effect on the blood pressure abnormalities of hyperandrogenic women taking oral contraceptives in a randomized clinical trial. <i>Scientific Reports</i> , 2021, 11, 22097.	1.6	0
20	Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas. <i>Journal of Clinical Medicine</i> , 2021, 10, 5509.	1.0	4
21	Postprandial inflammatory responses after oral glucose, lipid and protein challenges: Influence of obesity, sex and polycystic ovary syndrome. <i>Clinical Nutrition</i> , 2020, 39, 876-885.	2.3	20
22	Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 208-215.	2.4	7
23	Apparent mineralocorticoid excess as a side effect of ketoconazole therapy in a patient with Cushing's disease. <i>Clinical Endocrinology</i> , 2020, 92, 80-83.	1.2	2
24	A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1559-1576.	1.0	3
25	Fertility and Pregnancy Outcomes in Women with Polycystic Ovary Syndrome Following Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3384-e3391.	1.8	26
26	Changes in Soluble TWEAK Concentrations, but Not Those in Amyloid- $\beta$ (1-40), Are Associated with a Decrease in Carotid Intima-Media Thickness after Bariatric Surgery in Obese Women. <i>Obesity Facts</i> , 2020, 13, 321-330.	1.6	4
27	2D Diffusion-Ordered $^1\text{H}$ -NMR Spectroscopy Lipidomic Profiling after Oral Single Macronutrient Loads: Influence of Obesity, Sex, and Female Androgen Excess. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900928.	1.5	7
28	TLR2 and TLR4 Surface and Gene Expression in White Blood Cells after Fasting and Oral Glucose, Lipid and Protein Challenges: Influence of Obesity and Sex Hormones. <i>Biomolecules</i> , 2020, 10, 111.	1.8	19
29	Androgen Excess in Women: Proteomic and Metabolomic Approaches. <i>Frontiers of Hormone Research</i> , 2019, 53, 162-176.	1.0	3
30	Metabolic Cytokines at Fasting and During Macronutrient Challenges: Influence of Obesity, Female Androgen Excess and Sex. <i>Nutrients</i> , 2019, 11, 2566.	1.7	20
31	Glycoprotein A and B Height-to-Width Ratios as Obesity-Independent Novel Biomarkers of Low-Grade Chronic Inflammation in Women with Polycystic Ovary Syndrome (PCOS). <i>Journal of Proteome Research</i> , 2019, 18, 4038-4045.	1.8	36
32	Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test?. <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 86-92.	1.5	18
33	Association of Cardiovascular Autonomic Dysfunction With Peripheral Arterial Stiffness in Patients With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2675-2684.	1.8	12
34	Systemic endocrinopathies (thyroid conditions and diabetes): impact on postnatal life of the offspring. <i>Fertility and Sterility</i> , 2019, 111, 1076-1091.	0.5	7
35	Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2875-2891.	1.8	67
36	Polycystic ovary syndrome in adult women. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 450-457.	0.1	12

#	ARTICLE	IF	CITATIONS
37	Obesity and Reproduction. , 2019, , 543-552.		0
38	Lack of Improvement of Sperm Characteristics in Obese Males After Obesity Surgery Despite the Beneficial Changes Observed in Reproductive Hormones. Obesity Surgery, 2019, 29, 2045-2050.	1.1	17
39	Sexual Dimorphism and Sex Steroids Influence Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, e175-e178.	4.3	1
40	SÃ­ndrome de ovario poliquÃ­stico en la mujer adulta. Medicina ClÃ­nica, 2019, 152, 450-457.	0.3	22
41	The peripheral atherosclerotic profile in patients with type 1 diabetes warrants a thorough vascular assessment of asymptomatic patients. Diabetes/Metabolism Research and Reviews, 2019, 35, e3088.	1.7	15
42	Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. Metabolism: Clinical and Experimental, 2018, 86, 49-60.	1.5	63
43	Serum Retinol, Folic Acid, and Copper Are Associated With Sperm Abnormalities in Men With Obesity. Journal of the American College of Nutrition, 2018, 37, 194-200.	1.1	6
44	Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2018, 24, 225-241.	5.2	36
45	Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 2018, 14, 270-284.	4.3	1,013
46	Circulating adiponectin increases in obese women after sleeve gastrectomy or gastric bypass driving beneficial metabolic changes but with no relationship with carotid intima-media thickness. Clinical Nutrition, 2018, 37, 2102-2106.	2.3	10
47	Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes. Expert Opinion on Pharmacotherapy, 2018, 19, 1915-1926.	0.9	8
48	Certified testosterone immunoassays for hyperandrogenaemia. European Journal of Clinical Investigation, 2018, 48, e13029.	1.7	5
49	Gut Microbiota and the Polycystic Ovary Syndrome: Influence of Sex, Sex Hormones, and Obesity. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2552-2562.	1.8	201
50	Role of sampling times and serum cortisol cut-off concentrations on the routine assessment of adrenal function using the standard cosyntropin test in an academic hospital from Spain: a retrospective chart review. BMJ Open, 2018, 8, e019273.	0.8	11
51	Effects of glucose ingestion on circulating inflammatory mediators: Influence of sex and weight excess. Clinical Nutrition, 2017, 36, 522-529.	2.3	14
52	Improvement in cardiovascular risk in women after bariatric surgery as measured by carotid intima-media thickness: comparison of sleeve gastrectomy versus gastric bypass. Surgery for Obesity and Related Diseases, 2017, 13, 848-854.	1.0	16
53	Prevalence of "obesity-associated gonadal dysfunction"™ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Human Reproduction Update, 2017, 23, 390-408.	5.2	166
54	Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Human Reproduction Update, 2017, 23, 580-599.	5.2	136

#	ARTICLE	IF	CITATIONS
55	Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. <i>European Journal of Endocrinology</i> , 2017, 177, 399-408.	1.9	23
56	Plasma thiobarbituric acid reactive substances (TBARS) in young adults: Obesity increases fasting levels only in men whereas glucose ingestion, and not protein or lipid intake, increases postprandial concentrations regardless of sex and obesity. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1700425.	1.5	22
57	The Role of Androgen Excess in Metabolic Dysfunction in Women. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 597-608.	0.8	8
58	Sex differences in the characteristics and short-term prognosis of patients presenting with acute symptomatic pulmonary embolism. <i>PLoS ONE</i> , 2017, 12, e0187648.	1.1	39
59	Polycystic Ovary Syndrome: Implications for Cardiovascular, Endometrial, and Breast Disease. , 2017, , 456-457.		0
60	Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. <i>Diabetes Care</i> , 2016, 39, 639-648.	4.3	71
61	Serum Bioavailable Vitamin D Concentrations and Bone Mineral Density in Women After Obesity Surgery. <i>Obesity Surgery</i> , 2016, 26, 2732-2737.	1.1	7
62	The role of serum osteoprotegerin and receptorâ€“activator of nuclear factor-Î² ligand in metabolic bone disease of women after obesity surgery. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 655-661.	1.3	8
63	A nontargeted study of muscle proteome in severely obese women with androgen excess compared with severely obese men and nonhyperandrogenic women. <i>European Journal of Endocrinology</i> , 2016, 174, 389-398.	1.9	11
64	Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. <i>Andrology</i> , 2016, 4, 62-67.	1.9	71
65	Differences in analytical and biological results between older and newer lots of a widely used irisin immunoassay question the validity of previous studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e199-e201.	1.4	14
66	Association of TLR2 S450S and ICAM1 K469E polymorphisms with polycystic ovary syndrome (PCOS) and obesity. <i>Journal of Reproductive Immunology</i> , 2016, 113, 9-15.	0.8	13
67	Adrenal Hyperandrogenism and Polycystic Ovary Syndrome. <i>Current Pharmaceutical Design</i> , 2016, 22, 5588-5602.	0.9	25
68	Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2015, 103, 795-801.e2.	0.5	33
69	Treatment of hypothyroidism with levothyroxine or a combination of levothyroxine plus L-triiodothyronine. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 57-75.	2.2	20
70	Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, 603-610.	1.9	26
71	Targets to treat androgen excess in polycystic ovary syndrome. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1545-1560.	1.5	15
72	Identification of Reduced Circulating Haptoglobin Concentration as a Biomarker of the Severity of Pulmonary Embolism: A Nontargeted Proteomic Study. <i>PLoS ONE</i> , 2014, 9, e100902.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Surrogate Markers of Visceral Adiposity in Young Adults: Waist Circumference and Body Mass Index Are More Accurate than Waist Hip Ratio, Model of Adipose Distribution and Visceral Adiposity Index. PLoS ONE, 2014, 9, e114112.	1.1	86
74	Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2014, 20, 334-352.	5.2	389
75	Metabolomics in polycystic ovary syndrome. Clinica Chimica Acta, 2014, 429, 181-188.	0.5	41
76	The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European Journal of Endocrinology, 2014, 171, P1-P29.	1.9	502
77	Menstrual dysfunctionâ€”a proxy for insulin resistance in PCOS?. Nature Reviews Endocrinology, 2014, 10, 10-11.	4.3	12
78	Polycystic Ovary Syndrome as a Paradigm for Prehypertension, Prediabetes, and Preobesity. Current Hypertension Reports, 2014, 16, 500.	1.5	31
79	European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. European Journal of Endocrinology, 2014, 171, 489-498.	1.9	76
80	The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency. Human Reproduction, 2014, 29, 2083-2091.	0.4	79
81	Proteomic analysis of adipose tissue: informing diabetes research. Expert Review of Proteomics, 2014, 11, 491-502.	1.3	9
82	Effects of Bariatric Surgery on Male Obesity-Associated Secondary Hypogonadism: Comparison of Laparoscopic Gastric Bypass with Restrictive Procedures. Obesity Surgery, 2014, 24, 1686-1692.	1.1	55
83	Office Blood Pressure, Ambulatory Blood Pressure Monitoring, and Echocardiographic Abnormalities in Women With Polycystic Ovary Syndrome. Hypertension, 2014, 63, 624-629.	1.3	24
84	Role of Surgery in the Management of PCOS: Rationale and Considerations for Bariatric Surgery. , 2014, , 277-288.		0
85	Proteomic analysis of visceral adipose tissue in pre-obese patients with type 2 diabetes. Molecular and Cellular Endocrinology, 2013, 376, 99-106.	1.6	46
86	Proteomics and polycystic ovary syndrome. Expert Review of Proteomics, 2013, 10, 435-447.	1.3	25
87	Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Human Reproduction Update, 2013, 19, 268-288.	5.2	399
88	Effects of Polycystic Ovary Syndrome (PCOS), Sex Hormones, and Obesity on Circulating miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 Expression. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1835-E1844.	1.8	141
89	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2013, 19, 207-207.	5.2	6
90	Prevalence of hyperprolactinaemia in female premenopausal blood donors. Clinical Endocrinology, 2013, 79, 545-549.	1.2	12

#	ARTICLE	IF	CITATIONS
91	Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. <i>Molecular and Cellular Endocrinology</i> , 2013, 370, 65-77.	1.6	44
92	Evidence for Masculinization of Adipokine Gene Expression in Visceral and Subcutaneous Adipose Tissue of Obese Women With Polycystic Ovary Syndrome (PCOS). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E388-E396.	1.8	63
93	Global Adiposity and Thickness of Intraabdominal and Mesenteric Adipose Tissue Depots Are Increased in Women With Polycystic Ovary Syndrome (PCOS). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1254-1263.	1.8	103
94	A Nontargeted Proteomic Study of the Influence of Androgen Excess on Human Visceral and Subcutaneous Adipose Tissue Proteomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E576-E585.	1.8	46
95	Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. <i>Human Reproduction</i> , 2013, 28, 1908-1918.	0.4	60
96	Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS). <i>Current Pharmaceutical Design</i> , 2013, 19, 5775-5791.	0.9	69
97	Health and fertility in World Health Organization group 2 anovulatory women. <i>Human Reproduction Update</i> , 2012, 18, 586-599.	5.2	105
98	Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. <i>Human Reproduction</i> , 2012, 27, 3569-3576.	0.4	39
99	Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. <i>Human Reproduction</i> , 2012, 27, 1209-1216.	0.4	72
100	Androgens and polycystic ovary syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 91-102.	1.2	9
101	Management of Postmenopausal Virilization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2584-2588.	1.8	66
102	Surgical management of metabolic dysfunction in PCOS. <i>Steroids</i> , 2012, 77, 312-316.	0.8	23
103	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. <i>Human Reproduction Update</i> , 2012, 18, 146-170.	5.2	367
104	The R453Q and D151A polymorphisms of Hexose-6-Phosphate Dehydrogenase Gene (H6PD) influence the polycystic ovary syndrome (PCOS) and obesity. <i>Gene</i> , 2012, 497, 38-44.	1.0	14
105	Metabolic Heterogeneity in Polycystic Ovary Syndrome Is Determined by Obesity: Plasma Metabolomic Approach Using GC-MS. <i>Clinical Chemistry</i> , 2012, 58, 999-1009.	1.5	94
106	Iron metabolism and the polycystic ovary syndrome. <i>Trends in Endocrinology and Metabolism</i> , 2012, 23, 509-515.	3.1	61
107	A nontargeted proteomic approach to the study of visceral and subcutaneous adipose tissue in human obesity. <i>Molecular and Cellular Endocrinology</i> , 2012, 363, 10-19.	1.6	64
108	Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2011, 27, 978-981.	0.7	31



#	ARTICLE	IF	CITATIONS
109	Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. <i>Fertility and Sterility</i> , 2011, 95, 1048-1058.e2.	0.5	396
110	Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2011, 95, 1730-1735.e1.	0.5	13
111	Role of Decreased Circulating Hepcidin Concentrations in the Iron Excess of Women with the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 846-852.	1.8	81
112	Application of proteomics to the study of polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 869-75.	1.8	6
113	Retinol and Î±-Tocopherol in Morbid Obesity and Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2010, 20, 69-76.	1.1	61
114	Impact of the storage temperature on human plasma proteomic analysis: Implications for the use of human plasma collections in research. <i>Proteomics - Clinical Applications</i> , 2010, 4, 739-744.	0.8	18
115	The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. <i>Clinical Endocrinology</i> , 2010, 72, 383-392.	1.2	39
116	Obesity impairs general health-related quality of life (HR-QoL) in premenopausal women to a greater extent than polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , 2010, 73, 595-601.	1.2	19
117	Proteomic Analysis of Plasma in the Polycystic Ovary Syndrome Identifies Novel Markers Involved in Iron Metabolism, Acute-Phase Response, and Inflammation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3863-3870.	1.8	60
118	Treatment of Polycystic Ovary Syndrome (PCOS) with Metformin Ameliorates Insulin Resistance in Parallel with the Decrease of Serum Interleukin-6 Concentrations. <i>Hormone and Metabolic Research</i> , 2010, 42, 815-820.	0.7	34
119	Diagnosis and management of hirsutism. <i>Annals of the New York Academy of Sciences</i> , 2010, 1205, 166-174.	1.8	41
120	The determinants of insulin sensitivity, Î²-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. <i>Fertility and Sterility</i> , 2010, 94, 2214-2221.	0.5	32
121	Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2038-2049.	1.8	831
122	Role of Haptoglobin in Polycystic Ovary Syndrome (PCOS), Obesity and Disorders of Glucose Tolerance in Premenopausal Women. <i>PLoS ONE</i> , 2009, 4, e5606.	1.1	31
123	Serum Visceral Adipose Tissue-Derived Serine Protease Inhibitor Concentrations in Human Obesity and Polycystic Ovary Syndrome. <i>Diabetes Care</i> , 2009, 32, e6-e6.	4.3	18
124	Body Iron Stores and Glucose Intolerance in Premenopausal Women. <i>Diabetes Care</i> , 2009, 32, 1525-1530.	4.3	57
125	Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. <i>European Journal of Endocrinology</i> , 2009, 160, 469-480.	1.9	50
126	Antiandrogenic Contraceptives Increase Serum Adiponectin in Obese Polycystic Ovary Syndrome Patients. <i>Obesity</i> , 2009, 17, 3-9.	1.5	33



#	ARTICLE	IF	CITATIONS
127	Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2009, 91, 2527-2536.	0.5	36
128	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. <i>Fertility and Sterility</i> , 2009, 91, 456-488.	0.5	1,639
129	Reply of the Authors: Criteria for the polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2009, 92, e15.	0.5	2
130	HAPLOGENDIS INITIATIVE - SICA. <i>Acta Endocrinologica</i> , 2009, 5, 143-148.	0.1	1
131	The Increase in Serum Visfatin After Bariatric Surgery in Morbidly Obese Women is Modulated by Weight Loss, Waist Circumference, and Presence or Absence of Diabetes Before Surgery. <i>Obesity Surgery</i> , 2008, 18, 1000-1006.	1.1	29
132	Proteomics and genomics: A hypothesis-free approach to the study of the role of visceral adiposity in the pathogenesis of the polycystic ovary syndrome. <i>Proteomics - Clinical Applications</i> , 2008, 2, 444-455.	0.8	12
133	Polycystic ovary syndrome: treatment strategies and management. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2995-3008.	0.9	30
134	Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. <i>Human Reproduction</i> , 2008, 23, 1594-1601.	0.4	39
135	Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2008, 159, 225-232.	1.9	18
136	Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. <i>Human Reproduction</i> , 2008, 23, 651-661.	0.4	108
137	A Prospective Study of the Prevalence of Nonclassical Congenital Adrenal Hyperplasia among Women Presenting with Hyperandrogenic Symptoms and Signs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 527-533.	1.8	163
138	Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. <i>European Journal of Endocrinology</i> , 2007, 156, 539-545.	1.9	11
139	Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2007, 22, 3197-3203.	0.4	128
140	Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1209-1216.	1.8	96
141	Obesity Is the Major Determinant of the Abnormalities in Blood Pressure Found in Young Women with the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2141-2148.	1.8	65
142	Increased Body Iron Stores of Obese Women With Polycystic Ovary Syndrome Are a Consequence of Insulin Resistance and Hyperinsulinism and Are Not a Result of Reduced Menstrual Losses. <i>Diabetes Care</i> , 2007, 30, 2309-2313.	4.3	77
143	Differential Gene Expression Profile in Omental Adipose Tissue in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 328-337.	1.8	155
144	Comparison of Ethinyl-Estradiol Plus Cyproterone Acetate Versus Metformin Effects on Classic Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2453-2461.	1.8	92

#	ARTICLE	IF	CITATIONS
145	Abdominal adiposity and the polycystic ovary syndrome. Trends in Endocrinology and Metabolism, 2007, 18, 266-272.	3.1	333
146	Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clinical Nutrition, 2007, 26, 573-580.	2.3	214
147	The decrease in serum IL-18 levels after bariatric surgery in morbidly obese women is a time-dependent event. Obesity Surgery, 2007, 17, 1199-1208.	1.1	17
148	Genes Related to Metabolic Abnormalities or Insulin Resistance in Polycystic Ovary Syndrome. , 2007, , 49-67.		0
149	The decrease in serum IL-18 levels after bariatric surgery in morbidly obese women is a time-dependent event. Obesity Surgery, 2007, 17, 1199-1208.	1.1	3
150	Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4237-4245.	1.8	1,811
151	Reproductive Outcome of Women with 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3451-3456.	1.8	146
152	The PON1â€“108C/T polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women. Human Reproduction, 2006, 21, 3157-3161.	0.4	16
153	Genomic variants in polycystic ovary syndrome. Clinica Chimica Acta, 2006, 366, 14-26.	0.5	43
154	Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clinical Endocrinology, 2006, 65, 88-91.	1.2	42
155	Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Human Reproduction, 2006, 21, 2257-2265.	0.4	167
156	Hyperandrogenism, Insulin Resistance and Hyperinsulinemia as Cardiovascular Risk Factors in Diabetes Mellitus. Current Diabetes Reviews, 2006, 2, 39-49.	0.6	16
157	Mutations in the Hereditary Hemochromatosis Gene Are Not Associated With the Increased Body Iron Stores Observed in Overweight and Obese Women With Polycystic Ovary Syndrome. Diabetes Care, 2006, 29, 2556-2556.	4.3	14
158	Prevalence and Characteristics of the Polycystic Ovary Syndrome in Overweight and Obese Women. Archives of Internal Medicine, 2006, 166, 2081.	4.3	276
159	Mechanisms of Adaptation to Iodine Deficiency in Rats: Thyroid Status Is Tissue Specific. Its Relevance for Man. Endocrinology, 2006, 147, 2098-2108.	1.4	72
160	The ACAA-insertion/deletion polymorphism at the 3â€² UTR of the IGF-II receptor gene is associated with type 2 diabetes and surrogate markers of insulin resistance. European Journal of Endocrinology, 2006, 155, 331-336.	1.9	15
161	Effects of Thyroid Hormones on Serum Levels of Adipokines as Studied in Patients with Differentiated Thyroid Carcinoma During Thyroxine Withdrawal. Thyroid, 2006, 16, 397-402.	2.4	43
162	Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing <sc>l</sc>-Thyroxine plus Liothyronine with <sc>l</sc>-Thyroxine Alone. Annals of Internal Medicine, 2005, 142, 412.	2.0	158

#	ARTICLE	IF	CITATIONS
163	The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. <i>European Journal of Endocrinology</i> , 2005, 153, 223-230.	1.9	39
164	A Study of the Hexose-6-Phosphate Dehydrogenase Gene R453Q and 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Gene 83557insA Polymorphisms in the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4157-4162.	1.8	63
165	Body Iron Stores Are Increased in Overweight and Obese Women With Polycystic Ovary Syndrome. <i>Diabetes Care</i> , 2005, 28, 2042-2044.	4.3	43
166	Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. <i>Human Reproduction</i> , 2005, 20, 3184-3191.	0.4	70
167	Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4946-4954.	1.8	148
168	The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome. <i>Endocrine Reviews</i> , 2005, 26, 251-282.	8.9	359
169	The Polycystic Ovary Syndrome Associated with Morbid Obesity May Resolve after Weight Loss Induced by Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6364-6369.	1.8	351
170	Serum Interleukin-18 Concentrations Are Increased in the Polycystic Ovary Syndrome: Relationship to Insulin Resistance and to Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 806-811.	1.8	178
171	Weight Gain and Cardiovascular Risk Factors During Smoking Cessation with Bupropion or Nicotine. <i>Hormone and Metabolic Research</i> , 2004, 36, 178-182.	0.7	15
172	Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma.. <i>Endocrine-Related Cancer</i> , 2004, 11, 345-356.	1.6	57
173	Improved resolution of the human adipose tissue proteome at alkaline and wide range pH by the addition of hydroxyethyl disulfide. <i>Proteomics</i> , 2004, 4, 438-441.	1.3	55
174	Genetic Basis of Metabolic Abnormalities in Polycystic Ovary Syndrome. <i>Molecular Diagnosis and Therapy</i> , 2004, 4, 93-107.	3.3	34
175	Association of the Polycystic Ovary Syndrome with Genomic Variants Related to Insulin Resistance, Type 2 Diabetes Mellitus, and Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2640-2646.	1.8	146
176	Macroprolactinemia in women presenting with hyperandrogenic symptoms: Implications for the management of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2004, 82, 1697-1699.	0.5	21
177	Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. <i>Diabetologia</i> , 2003, 46, 625-633.	2.9	137
178	Association of Polymorphisms in the Interleukin 6 Receptor Complex with Obesity and Hyperandrogenism. <i>Obesity</i> , 2003, 11, 987-996.	4.0	81
179	Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2003, 79, 219-220.	0.5	49
180	Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.. <i>Endocrine-Related Cancer</i> , 2003, 10, 601-610.	1.6	94

#	ARTICLE	IF	CITATIONS
181	The -597 G→A and -174 G→C Polymorphisms in the Promoter of the IL-6 Gene Are Associated with Hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1134-1141.	1.8	100
182	The Methionine 196 Arginine Polymorphism in Exon 6 of the TNF Receptor 2 Gene (TNFRSF1B) Is Associated with the Polycystic Ovary Syndrome and Hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3977-3983.	1.8	92
183	Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. <i>Fertility and Sterility</i> , 2002, 77, 581-587.	0.5	33
184	Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. <i>Fertility and Sterility</i> , 2002, 77, 666-668.	0.5	41
185	The -597 G→A and -174 G→C Polymorphisms in the Promoter of the IL-6 Gene Are Associated with Hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1134-1141.	1.8	73
186	Role of the pentanucleotide (tttta) <sub>n</sub> polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. <i>Fertility and Sterility</i> , 2001, 75, 797-802.	0.5	59
187	Role of the follistatin gene in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2001, 75, 1020-1023.	0.5	33
188	TNF- $\alpha$ and Hyperandrogenism: A Clinical, Biochemical, and Molecular Genetic Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3761-3767.	1.8	22
189	Eflornithine. <i>American Journal of Clinical Dermatology</i> , 2001, 2, 202.	3.3	1
190	The pediatric origins of polycystic ovary syndrome. , 2001, , 233-261.		0
191	Identification of the Source of Androgen Excess in Hyperandrogenic Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2001, 24, 1297-1299.	4.3	42
192	Screening for Mutations in the Steroidogenic Acute Regulatory Protein and Steroidogenic Factor-1 Genes, and in CYP11A and Dosage-Sensitive Sex Reversal-Adrenal Hypoplasia Gene on the X Chromosome, Gene-1 (DAX-1), in Hyperandrogenic Hirsute Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1746-1749.	1.8	20
193	Screening for Mutations in the Steroidogenic Acute Regulatory Protein and Steroidogenic Factor-1 Genes, and in CYP11A and Dosage-Sensitive Sex Reversal-Adrenal Hypoplasia Gene on the X Chromosome, Gene-1 (DAX-1), in Hyperandrogenic Hirsute Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1746-1749.	1.8	19
194	Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. <i>Clinical Endocrinology</i> , 2000, 53, 313-319.	1.2	26
195	Serum Prostate-Specific Antigen Concentrations Are Not Useful for Monitoring the Treatment of Hirsutism with Oral Contraceptive Pills. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2488-2492.	1.8	23
196	A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2434-2438.	1.8	845
197	The Role of the CAG Repeat Polymorphism in the Androgen Receptor Gene and of Skewed X-Chromosome Inactivation, in the Pathogenesis of Hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1735-1740.	1.8	71
198	Treatment of hirsutism with ethinyl estradiol+desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. <i>Fertility and Sterility</i> , 2000, 74, 816-819.	0.5	66

#	ARTICLE	IF	CITATIONS
199	High Prevalence of the Polycystic Ovary Syndrome and Hirsutism in Women with Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4182-4187.	1.8	81
200	The Role of the CAG Repeat Polymorphism in the Androgen Receptor Gene and of Skewed X-Chromosome Inactivation, in the Pathogenesis of Hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1735-1740.	1.8	56
201	Serum Prostate-Specific Antigen Concentrations Are Not Useful for Monitoring the Treatment of Hirsutism with Oral Contraceptive Pills. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2488-2492.	1.8	12
202	Tissue-specific patterns of changes in 3,5,3- <sup>2</sup> -triiodo-L-thyronine concentrations in thyroidectomized rats infused with increasing doses of the hormone. Which are the regulatory mechanisms?. <i>Biochimie</i> , 1999, 81, 453-462.	1.3	41
203	Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. <i>Fertility and Sterility</i> , 1999, 71, 122-128.	0.5	43
204	The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. <i>Fertility and Sterility</i> , 1999, 72, 629-638.	0.5	74
205	Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism. <i>Fertility and Sterility</i> , 1998, 70, 1090-1100.	0.5	17
206	The Increased Circulating Prostate-Specific Antigen Concentrations in Women with Hirsutism Do Not Respond to Acute Changes in Adrenal or Ovarian Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2580-2584.	1.8	37
207	The Increased Circulating Prostate-Specific Antigen Concentrations in Women with Hirsutism Do Not Respond to Acute Changes in Adrenal or Ovarian Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2580-2584.	1.8	9
208	Thyroid Hormones Influence Serum Leptin Concentrations in the Rat. <i>Endocrinology</i> , 1997, 138, 4485-4488.	1.4	112
209	Regulation of Iodothyronine Deiodinase Activity as Studied in Thyroidectomized Rats Infused with Thyroxine or Triiodothyronine<sup>1</sup>. <i>Endocrinology</i> , 1997, 138, 2559-2568.	1.4	85
210	Methimazole-Induced Severe Aplastic Anemia: Unsuccessful Treatment with Recombinant Human Granulocyte-Monocyte Colony-Stimulating Factor. <i>Thyroid</i> , 1997, 7, 67-70.	2.4	29
211	Circulating leptin concentrations in women with hirsutism. <i>Fertility and Sterility</i> , 1997, 68, 898-906.	0.5	42
212	Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. <i>Fertility and Sterility</i> , 1997, 67, 654-662.	0.5	28
213	Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: Does idiopathic hirsutism exist?. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 902-907.	1.5	49
214	Thyroid Hormones Influence Serum Leptin Concentrations in the Rat. <i>Endocrinology</i> , 1997, 138, 4485-4488.	1.4	35
215	Regulation of Iodothyronine Deiodinase Activity as Studied in Thyroidectomized Rats Infused with Thyroxine or Triiodothyronine. <i>Endocrinology</i> , 1997, 138, 2559-2568.	1.4	19
216	Cardiac Involvement in Acromegaly: Specific Myocardiopathy or Consequence of Systemic Hypertension?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1047-1053.	1.8	85

#	ARTICLE	IF	CITATIONS
217	Effects of L-Arginine Infusion on Renal Hemodynamics and Sodium Excretion During Hypo-, Normo-, and Hyperinsulinemia, as Studied in Dogs. American Journal of Hypertension, 1996, 9, 681-686.	1.0	3
218	Methimazole Has No Dose-Related Effect on the Serum Concentrations of Soluble Class I Major Histocompatibility Complex Antigens, Soluble Interleukin-2 Receptor, and $\beta_2$ -Microglobulin in Patients with Graves' Disease. Thyroid, 1996, 6, 29-36.	2.4	31
219	Insulin resistance in patients with a recent diagnosis of coronary artery disease. Journal of Hypertension, 1996, 14, 1477-1482.	0.3	13
220	Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology, 1996, 137, 2490-2502.	1.4	58
221	Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats.. Journal of Clinical Investigation, 1995, 96, 2828-2838.	3.9	249
222	Isolated adrenocorticotrophic hormone deficiency due to probable lymphocytic hypophysitis in a man. Journal of Endocrinological Investigation, 1994, 17, 127-131.	1.8	39
223	Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperandrogenism: role of adrenal and ovarian cytochrome P450c17 $\alpha$ . Fertility and Sterility, 1994, 62, 521-530.	0.5	35
224	Hirsutism: managing the basics. , 0, , 1-10.		0